Medicaid Managed Care Open Enrollment Extended through Dec. 15
Current Suspected Overdose Deaths in Delaware for 2017: 223

Delaware.gov logo

Delaware Health Alert Network #151

June 5, 2008, 4:05 pm


Health Advisory
TEMPORARY UNAVAILABILITY OF RABIES PRE-EXPOSURE VACCINATION


Current Situation

  • Effective May 19th, 2008, Sanofi Pasteur maker of IMOVAX Rabies (Rabies Vaccine) will temporarily only be available for post-exposure prophylaxis.
  • Sanofi Pasteur will continue to supply their vaccine to health care providers, who in consultation with public health, are treating patients who have had documented rabies exposures.
  • These measures will allow responsible management of currently limited supplies of this vaccine.
  • Novartis, the other supplier of rabies vaccine in the US, currently has limited amounts of rabies vaccine, RabAvert, which is available for Post Exposure Prophylaxis use only. It is expected that additional RabAvert will be available to the market by approximately July 2008. It is hoped that the demand for pre-exposure vaccine supplies will be met at this time.
  • Discussions among federal, state, and local public health personnel are ongoing to review additional strategies to handle Pre-Exposure Prophylaxis vaccination needs.

Why is there an interruption in supply?

  • Starting in June 2007, Sanofi Pasteur began renovating its IMOVAX Rabies vaccine production facility in France to maintain compliance with the most current requirements from FDA and the French regulatory body. Prior to these renovations, Sanofi Pasteur established an inventory based on historical levels of sales and projected market demand. The facility is scheduled to be approved and operational by mid-to-late 2009. Until the facility is operational, Sanofi Pasteur has a finite amount of IMOVAX Rabies vaccine.
  • After the renovations began, Novartis, the other supplier of rabies vaccine for the United States, was unable to meet projected rabies vaccine supplies.
  • Since early 2008, Novartis has been supplying its rabies vaccine, RabAvert, for post-exposure use only. Consequently, Sanofi Pasteur has been supplying nearly all of the market for rabies vaccine. The increase in demand for IMOVAX is outpacing the company’s historical levels of supply.

How does this affect current rabies vaccination recommendations?

  • Pre-Exposure Prophylaxis should be delayed until vaccine is available. It is expected that additional vaccine will be available again around July 2008.
  • Persons at increased risk for rabies exposure should take appropriate precautions to avoid rabies exposure.
  • Vaccine is available for Post Exposure Prophylaxis, and providers should consult with the Division of Public Health’s Rabies Program (302-744-4545) to ensure appropriate use of vaccine.
  • General rabies awareness and prevention messages should be emphasized to avoid exposure (e.g., avoid wildlife contact, vaccinate pets/livestock, capture/observe/test exposing animal, etc.)

For additional information

Call the Division of Public Health’s Rabies Program Hotline at 302-744-4545 or log on to:

http://www.cdc.gov/rabies/qanda/rabiesbiol.html or

http://www.cdc.gov/rabies/qanda/general.html

Categories of Health Alert messages:

  • Health Alert: Conveys the highest level of importance; warrants immediate action or attention.
  • Health Advisory: Provides important information for a specific incident or situation; may not require immediate action.
  • Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action.
NOTE: This page is for informational purposes only and dated material (e.g. temporary websites) may not be available.



+